News
CSTL
34.50
+1.50%
0.51
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
PR Newswire · 12h ago
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
PR Newswire · 1d ago
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
PR Newswire · 1d ago
Guggenheim Remains a Buy on Castle Biosciences (CSTL)
TipRanks · 2d ago
Castle Biosciences Price Target Raised to $52.00/Share From $44.00 by BTIG
Dow Jones · 2d ago
Castle Biosciences Is Maintained at Buy by BTIG
Dow Jones · 2d ago
Castle Biosciences price target raised to $52 from $44 at BTIG
TipRanks · 3d ago
Castle Biosciences Price Target Raised to $41.00/Share From $39.00 by Baird
Dow Jones · 3d ago
Castle Biosciences Is Maintained at Outperform by Baird
Dow Jones · 3d ago
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $41
Benzinga · 3d ago
Castle Biosciences price target raised to $41 from $39 at Baird
TipRanks · 3d ago
Weekly Report: what happened at CSTL last week (1102-1106)?
Weekly Report · 3d ago
Castle Biosciences (CSTL) Receives a Buy from Canaccord Genuity
TipRanks · 6d ago
Castle Biosciences Is Maintained at Overweight by Keybanc
Dow Jones · 6d ago
Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $40
Benzinga · 6d ago
Castle Biosciences price target raised to $40 from $35 at KeyBanc
TipRanks · 6d ago
Castle Biosciences price target raised to $39 from $38 at Baird
TipRanks · 6d ago
Castle Biosciences (CSTL) Gets a Buy from KeyBanc
TipRanks · 6d ago
Castle Biosciences Q3 2026 Earnings Call Transcript
Benzinga · 11/05 22:21
Castle Biosciences Non-GAAP EPS of -$0.13 beats by $0.22, revenue of $102.9M beats by $9.99M
Seeking Alpha · 11/05 22:19
More
Webull provides a variety of real-time CSTL stock news. You can receive the latest news about Castle Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).